CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical
company discovering and developing protein therapeutics to treat
diseases of the eye, today announced the election of Paul Chaney,
President and Chief Executive Officer of PanOptica, Inc., to the
Company's board of directors.
"Paul brings nearly 30 years of experience in the pharmaceutical
industry, including 19 years of ophthalmic pharmaceutical development
and commercial leadership experience, to Eleven," said Abbie Celniker,
Ph.D., President and Chief Executive Officer of Eleven. "Paul's skills
and experience in leading ophthalmology-focused biotechnology companies
and pharmaceutical company business units will be valuable to Eleven as
the Company advances its ophthalmic development programs."
Paul Chaney is President and Chief Executive Officer of PanOptica, a
private, venture-backed biopharmaceutical company focused on developing
innovative ophthalmic therapeutics. Prior to co-founding PanOptica in
2009, Paul was Executive Vice President of OSI Pharmaceuticals, Inc. and
President of (OSI) Eyetech, Inc., OSI Pharmaceuticals' wholly-owned
eyecare subsidiary. He joined Eyetech Pharmaceuticals, Inc. as Chief
Operating Officer in 2003. Prior to joining Eyetech, Paul held a variety
of senior management positions at Pharmacia Corporation, including Vice
President of the Global Ophthalmology Business and Vice President of
Global Pharmaceutical Ophthalmology. He began his career as a sales
representative for The Upjohn Company in 1980. Paul earned a dual degree
in Biological Sciences and English from the University of Delaware.
About Eleven Biotherapeutics
Eleven Biotherapeutics is a clinical-stage biopharmaceutical company
with a proprietary protein engineering platform, called AMP-Rx, that it
applies to the discovery and development of protein therapeutics to
treat diseases of the eye. The Company's therapeutic approach is based
on the role of cytokines in diseases of the eye, the Company's
understanding of the structural biology of cytokines and the Company's
ability to rationally design and engineer proteins to modulate the
effects of cytokines. Cytokines are cell signaling molecules found in
the body that can have important inflammatory effects.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the Company's
strategy, future operations, advancement of the Company's development
programs, clinical development of the Company's therapeutic candidates
and future value or contributions of individuals to the Company, and
other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project,"
"target," "potential," "will," "would," "could," "should," "continue,"
and similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation and conduct of
clinical trials, availability and timing of data from ongoing clinical
trials, whether results of early clinical trials will be indicative of
the results of future trials and other factors discussed in the "Risk
Factors" section of the Company's prospectus filed with the Securities
and Exchange Commission pursuant to Rule 424(b)(4) on February 6, 2014.
In addition, the forward-looking statements included in this press
release represent the Company's views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's views as of any date subsequent to the date hereof.
Cameron Wheeler, PhD, 617-858-0927
Gina Nugent, 617-460-3579
Source: Eleven Biotherapeutics
News Provided by Acquire Media